You are here: Industry Insights > Hemophilia A

News List

Sangamo, Pfizer Announce First Patient Receives SB-525 Treatment in Clinical Trial expressbpd
August 28, 2017
Sangamo Therapeutics and Pfizer announced the first patient received treatment in the Phase 1/2 clinical trial (Alta trial) evaluating SB-525, an investigational gene therapy for patients with Hemophilia A, a rare genetic blood disorder.
Roche gets priority review for hyped hemophilia A prospect fiercebiotech
August 25, 2017
The FDA has granted priority review status to Roche’s hemophilia A candidate emicizumab, setting up the Swiss drugmaker to learn its fate by Feb. 23. Roche enters the review process armed with impressive efficacy data that risks being undermined by safety
FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors August 25, 2017
Genentech announced the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis (preventative) as a once-weekly subcutaneous treatment for adults, adoles
Shire submits IND application to FDA for gene therapy candidate SHP654 for treatment of hemophilia A cphi-online
July 13, 2017
SHP654 aims to deliver sustained protection against bleeds for patients with hemophilia A.
Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemo americanpharmaceuticalreview
April 18, 2017
Genentech has announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII.

Previous page 1 2 Next page